drugset / Trial / NCT04246190

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

NCT04246190

Phase 1 Unknown 26 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.

Timeline

Start
2020-02-24
Primary completion
2020-04-10
Completion
2020-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-396 Unknown Oral
Subject D759 Unknown Oral
Subject Lobeglitazone Small molecule Oral